SNTI
Senti Biosciences, Inc.NASDAQHealthcare$0.91+6.52%ClosedMarket Cap: $24.0M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
3.67
P/S
1089.99
EV/EBITDA
-0.63
DCF Value
$-0.07
FCF Yield
-182.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
-14777.3%
Operating Margin
-289668.2%
Net Margin
-279263.6%
ROE
-322.4%
ROA
-119.9%
ROIC
-149.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $22.0K | -3959.1% | $-13.6M | $-14.5M | $-0.53 | — |
| FY 2025 | $22.0K | -16431.8% | $-63.7M | $-61.4M | $-2.73 | — |
| Q3 2025 | $0.00 | -Infinity% | $-16.9M | $-18.1M | $-0.69 | — |
| Q2 2025 | $0.00 | -Infinity% | $-16.8M | $-14.7M | $-0.56 | — |
| Q1 2025 | $0.00 | NaN% | $-16.4M | $-14.1M | $-3.07 | — |
| Q4 2024 | $0.00 | -Infinity% | $-16.2M | $-610.0K | $-0.13 | — |
| FY 2024 | $0.00 | NaN% | $-61.0M | $-52.8M | $-11.49 | — |
| Q3 2024 | $0.00 | NaN% | $-15.2M | $-28.9M | $-6.31 | — |
| Q2 2024 | $0.00 | -Infinity% | $-13.4M | $-11.2M | $-2.45 | — |
| Q1 2024 | $0.00 | -Infinity% | $-16.3M | $-12.1M | $-2.65 | — |
| Q4 2023 | $0.00 | -Infinity% | $-18.4M | $-18.7M | $-4.16 | — |
| FY 2023 | $2.0M | 100.0% | $-92.7M | $-71.1M | $-20.94 | — |